Tenaya Therapeutics Inc TNYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
-
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
-
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
-
Tenaya Therapeutics Says FDA Hold Lifted on Heart Disease Trial
Trading Information
- Previous Close Price
- $0.39
- Day Range
- $0.38–0.40
- 52-Week Range
- $0.36–1.72
- Bid/Ask
- $0.39 / $0.39
- Shares Outstanding
- 224.23M
- Market Cap
- $87.23M
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 56.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 70
Valuation
|
Metric
|
TNYA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.26 |
Price/Sales | 56.36 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TNYA
|
|---|---|
Quick Ratio | 4.12 |
Current Ratio | 4.52 |
Interest Coverage | — |
Quick Ratio
TNYA
Profitability
|
Metric
|
TNYA
|
|---|---|
Return on Assets (Normalized) | −58.37% |
Return on Equity (Normalized) | −73.04% |
Return on Invested Capital (Normalized) | −68.91% |
Return on Assets
TNYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Q?%kv@ | LOCK|^wgK& | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&<>GvM | LOCK|^$Xzw | $83B | |||
| Moderna Inc
MRNA
| LOCK|Y%N^^$& | LOCK|&J | $80B | |||
| argenx SE ADR
ARGX
| LOCK|&@b?@&v | LOCK|?Mh | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|m%S%^<s | LOCK|DvR | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y%>bQ! | LOCK|ZQyXN | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@bdJ$Pm | LOCK|qWM@ | $28B | |||
| Incyte Corp
INCY
| LOCK|t@@z&VR | LOCK|%p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|vT#nl>g | LOCK|bCl | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|cK$^B& | LOCK|!@ | $14B |
United States